Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Updated Cholesterol Guidelines Support More Intensive Lowering of Cholesterol

14.07.2004


The National Cholesterol Education Program (NCEP) has updated its guidelines for treatment of blood cholesterol, suggesting that people at risk for heart attack and stroke would benefit from more intensive cholesterol-lowering therapies.



Dr. Scott M. Grundy, director of the Center for Human Nutrition at UT Southwestern Medical Center at Dallas, said the new guidelines are based largely on results from five major clinical trials involving cholesterol-lowering medications called statins. These results make possible changes to the 2001 guidelines issued by the NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), for which Dr. Grundy served as chairman. The updated recommendations – published today in Circulation: Journal of the American Heart Association – are endorsed by the National Heart, Lung and Blood Institute; the American Heart Association; and the American College of Cardiology.

NCEP identifies three categories of risk based on a person’s likelihood to develop cardiovascular disease (heart attack and stroke) in the near future: high risk, moderately high risk, and lower to moderate risk. High-risk individuals are those who have already had a heart attack; cardiac chest pain (angina); previous angioplasty or bypass surgery; obstructed blood vessels to the arms, legs or brain; diabetes; or a collection of other risk factors that raise the likelihood of having a heart attack in the next 10 years by more than 20 percent.


For high-risk patients, the guidelines issued in 2001 called for doctors to prescribe cholesterol-lowering drugs along with dietary therapy as necessary to reduce low-density lipoprotein (LDL) cholesterol levels to less than 100 milligrams per deciliter. Recent clinical trials allowed the panel to identify a subgroup of high-risk patients who can be considered to be at very high risk and may benefit from even more intensive lowering of LDL. For very high-risk persons, the new recommendations give physicians the option of reducing LDL cholesterol to less than 70 mg/dL.

Patients are considered at very high risk if they already have cardiovascular disease plus diabetes, are persistent smokers, have poorly controlled high blood pressure, recently suffered a heart attack, or have the metabolic syndrome – a constellation of risk factors that include overweight and obesity, high triglycerides, low levels of “good” high-density lipoprotein (HDL) cholesterol, high blood pressure, high blood glucose and a tendency to form blood clots.

For people who are at moderately high risk – those who have two or more risk factors for coronary heart disease and have a 10 percent to 20 percent chance of having a heart attack in the next 10 years – ATP III recommended reducing LDL cholesterol to less than 130 mg/dL. Recent clinical trials, however, strongly suggest that moderately high-risk people will receive additional benefit if their LDL levels are reduced to less than 100 mg/dL.

Recent clinical trials also provide strong evidence that cholesterol-lowering therapy is effective in reducing cardiovascular disease in patients with diabetes as well as older persons who are at risk. Guidelines for people with lower to moderate risk for cardiovascular disease were unchanged.

“The report also emphasizes the importance of making lifestyle changes that help with cholesterol management, including eating a low-saturated fat, low-cholesterol diet; increasing fiber intake; losing weight, and exercising regularly,” Dr. Grundy said. “These should always be employed when patients are given cholesterol-lowering drugs.”

The first ATP report, published in 1988, focused on the prevention of coronary heart disease before any signs of clinical disease. This report identified LDL cholesterol as the major form of “bad” cholesterol and the primary target of treatment. In the second report in 1993, the panel reaffirmed the importance of treating high LDL cholesterol. It showed that patients who already have cardiovascular disease benefit from cholesterol-lowering therapy. The 2001 ATP report went a step further, outlining more intensive treatments for people at high risk who do not yet have cardiovascular disease. Dr. Grundy was a member of the panel that produced the first report and was chairman of the panel that wrote the second and third reports.

“It has been gratifying to see research in the cholesterol field come to fruition to save so many lives,” he said.

The National Heart, Lung and Blood Institute, part of the National Institutes of Health, established the National Cholesterol Education Program in 1985.

| newswise
Further information:
http://www.utsouthwestern.edu

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>